Omeros (OMER) Projected to Release Earnings on Thursday

Key Points

• Omeros is expected to report Q3 2026 results after market close on November 12, with analysts forecasting earnings of $0.02 per share and revenue of $37.28 million.
• In its prior quarter, Omeros reported $0.02 EPS and $28.53 million in revenue, beating analyst estimates for both. Analysts project full-year EPS of -$0.37 this fiscal year and $1.21 next fiscal year.
• The stock has a “Moderate Buy” consensus rating and an average price target of $30.33. Insiders sold about 105,906 shares worth nearly $2 million over the last quarter.

Omeros (NASDAQ:OMER - Get Free Report) is expected to be announcing its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect Omeros to post earnings of $0.02 per share and revenue of $37.28 million for the quarter. Individuals are encouraged to explore the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Omeros (NASDAQ:OMER - Get Free Report) last announced its earnings results on Wednesday, August 12th. The biopharmaceutical company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.27) by $0.29. The company had revenue of $28.53 million for the quarter, compared to analysts' expectations of $12.69 million. On average, analysts expect Omeros to post ($0.37) EPS for the current fiscal year and $1.21 EPS for the next fiscal year.

Omeros Price Performance

NASDAQ:OMER opened at $18.18 on Thursday. Omeros has a 1-year low of $6.24 and a 1-year high of $21.24. The firm has a 50-day moving average of $18.45 and a two-hundred day moving average of $13.55. The stock has a market cap of $1.32 billion, a P/E ratio of 6.69 and a beta of 2.96.

Wall Street Analysts Forecast Growth

OMER has been the topic of a number of recent research reports. Zacks Research downgraded shares of Omeros from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 13th. HC Wainwright reaffirmed a "buy" rating on shares of Omeros in a report on Monday, July 27th. Cantor Fitzgerald restated an "overweight" rating and issued a $22.00 target price on shares of Omeros in a report on Wednesday, October 14th. Weiss Ratings raised shares of Omeros from a "hold (c-)" rating to a "hold (c)" rating in a research note on Thursday, October 8th. Finally, Wall Street Zen raised Omeros from a "hold" rating to a "buy" rating in a research note on Saturday, August 15th. Three equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Omeros currently has a consensus rating of "Moderate Buy" and an average target price of $30.33.

Insiders Place Their Bets

In related news, VP Peter Cancelmo sold 25,000 shares of the stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $18.54, for a total transaction of $463,500.00. Following the completion of the sale, the vice president owned 200 shares in the company, valued at $3,708. This represents a 99.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Thomas Cable sold 15,000 shares of the stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $18.45, for a total transaction of $276,750.00. Following the completion of the sale, the director directly owned 35,067 shares of the company's stock, valued at approximately $646,986.15. This trade represents a 29.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 105,906 shares of company stock worth $1,989,705 over the last quarter. 10.50% of the stock is currently owned by company insiders.

About Omeros

Omeros Corporation NASDAQ: OMER is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994.

Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.